Immuneering appoints Grant C. Bogle to board as Class III Director

Immuneering Corporation filed a Form 8-K on November 9, 2026 disclosing a change to its board of directors. On that date, the Board of Directors of Immuneering appointed Grant C. Bogle, MBA, to serve as a member of the Company's Board as a Class III Director.¹

The filing states that Bogle will receive compensation in accordance with the Company's compensation arrangements for non-employee directors.¹ As of the filing date, Bogle has not been appointed to a committee of the Board of Directors.¹

The company also addressed the circumstances of the appointment, stating that there was no arrangement or understanding pursuant to which Bogle was elected as a director.¹ Separately, Bogle has entered into the Company's standard indemnification agreement for directors and officers.¹

Immuneering Corporation is incorporated in Delaware and is headquartered at 245 Main St., Second Floor, Cambridge, MA 02142. The company's Class A common stock trades on the Nasdaq Global Market under the ticker symbol IMRX.

The 8-K was signed by Michael D. Bookman, Chief Legal Officer and Secretary, on November 9, 2026, the same date as the reported board action.